NASDAQ:NUVB 20 November 2025 - 12 January 2026

For live price, interactive charts, financials and the latest market data, visit Google Finance.

Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens

Nuvation Bio Inc shares tumbled almost 18% on Monday following news of a licensing deal with Japan’s Eisai and initial sales data for its lung-cancer treatment. The stock slipped 17.7% to $6.62, after fluctuating between $8.34 and $6.32 on roughly 11.4 million shares traded.

12 January 2026

Biotechnology·Earnings Reports·NASDAQ:NUVB·Stock Market·TSX:4523

Nuvation Bio stock falls as UBS starts coverage; NUVB investors eye JPM conference next week

Nuvation Bio Inc shares slid about 4.7% to $8.05 Friday afternoon, after earlier hitting a session low of $8.05.

9 January 2026

NASDAQ:NUVB·Stock Market

Nuvation Bio stock today: NUVB slides nearly 7% as early gains fade

Shares of Nuvation Bio Inc fell about 6.8% to $8.35 in afternoon trading on Friday, after opening at $8.97 and swinging between $9.13 and $8.30. About 3.3 million shares had changed hands.

2 January 2026

Biotechnology·NASDAQ:NUVB·Stock Market

Nuvation Bio (NUVB) Rockets to 3‑Year High as Wall Street Lifts Price Targets on IBTROZI Momentum – November 20, 2025

Nuvation Bio Inc. has become one of the hottest tickers in biotech this week. On November 20, 2025, NUVB is trading near a three‑year high after a powerful earnings beat, accelerating uptake of its lung‑cancer drug IBTROZI™, and a wave of bullish analyst upgrades that continue to roll in today. Seeking Alpha+2Trefis+2

20 November 2025

NASDAQ:NUVB·Stock Market

Go toTop